Theravance Biopharma (NASDAQ:TBPH) Releases Quarterly Earnings Results, Misses Expectations By $0.26 EPS

Theravance Biopharma (NASDAQ:TBPH) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.26), Zacks reports. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%.

Theravance Biopharma Trading Up 1.2 %

NASDAQ:TBPH traded up $0.11 during trading hours on Wednesday, reaching $9.08. 276,927 shares of the company traded hands, compared to its average volume of 204,412. The stock has a market capitalization of $446.50 million, a P/E ratio of -8.99 and a beta of 0.21. The business’s 50-day moving average price is $9.36 and its two-hundred day moving average price is $8.91. Theravance Biopharma has a 1 year low of $7.44 and a 1 year high of $10.90.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at $2,786,085. This trade represents a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 6.90% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a research note on Tuesday. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $13.75.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.